The cornerstone of this breakthrough lies in the strategic pairing of aluminum hydroxide — commonly known as alum and widely used in existing vaccines — with an advanced saponin-based adjuvant nanoparticle, referred to as SMNP. Alum is renowned for triggering innate immune responses and facilitating antigen retention, while SMNP, derived from the bark of the Chilean soapbark tree, initiates robust inflammatory signaling pathways. Their combined effect profoundly amplifies the quality and longevity of the immune activation, especially within the germinal centers located in lymph nodes.

Within these germinal centers, B cells undergo an intricate process of selection and mutation, refining their antibody affinity and breadth. The study, conducted in mice, demonstrated that vaccines crafted with both alum and SMNP not only penetrate lymph node barriers effectively but also maintain the integrity of the HIV antigen—specifically the engineered MD39 protein—for extended periods, up to 28 days. This prolonged antigen presence mimics natural infection dynamics, allowing B cells repeated exposure and continuous affinity maturation.

This dual-adjuvant formulation significantly expands the diversity of the B cell repertoire. Leveraging single-cell RNA sequencing techniques, the researchers uncovered that mice receiving the combined vaccine exhibited two-to-three times the number of unique B cell clones than those vaccinated with a single adjuvant. Such clonal expansion is critical for producing broadly neutralizing antibodies capable of targeting diverse and evolving viral strains, a milestone especially vital for combating viruses like HIV, known for their high mutation rates.

The intricate interplay between the antigen, alum, and SMNP induces a highly supportive microenvironment that encourages germinal center reactions optimized for clonal selection and expansion. By avoiding premature antigen degradation in the lymph nodes, this vaccine platform offers B cells iterative opportunities to refine their antibody genes via somatic hypermutation. This dynamic is essential for developing antibodies with heightened specificity and neutralization breadth, which are considered the “holy grail” in vaccine design, particularly against mutable pathogens.

Importantly, the study outlines that combining these adjuvants exerts an additive or even synergistic effect without necessitating novel or untested components. Both alum and saponin-based adjuvants have established safety profiles and regulatory acceptance, which potentially accelerates regulatory approvals for vaccines employing this method. Furthermore, the platform’s adaptability makes it applicable to a wide range of protein-based immunogens, suggesting its utility beyond HIV to encompass influenza, SARS-CoV-2, and emerging pandemic threats.

The implications of this research extend into the realm of vaccine logistics and global health. By enabling potent immune responses with a single administration, the approach surmounts challenges associated with multi-dose schedules, which often hinder vaccine coverage in resource-limited environments. Simplifying vaccination regimens increases compliance and facilitates rapid mass immunization, a critical component in epidemic and pandemic preparedness.

Moreover, the molecular design of anchoring multiple copies of the HIV MD39 antigen onto alum particles ensures a concentrated presentation of the antigen within lymph nodes. This dense display optimizes B cell receptor engagement and cross-linking, a prerequisite for initiating potent germinal center reactions. The Scripps and MIT teams’ choice of the MD39 antigen, known for its stabilized trimeric structure mimicking the native HIV envelope, further enhances immune recognition.

Another novel aspect lies in the ability of the adjuvants to facilitate antigen translocation across the lymph node subcapsular sinus without fragmentation, a biological barrier that typically limits antigen availability. By circumventing this obstacle, the vaccine ensures that native-like antigens are presented to B cells as intact conformations, crucial for generating high-affinity antibodies that recognize the virus authentically.

The dual-adjuvant vaccine’s capacity to sustain antigen release equates to a form of controlled, slow-release delivery, extending immune system stimulation over weeks rather than hours or days. This persistent stimulation is well-aligned with natural infection kinetics, wherein continuous antigenic presence drives robust long-term immunity and immune memory—a phenomenon difficult to replicate with conventional vaccine formulations.

With these promising preclinical findings, the vaccine formulation is poised for further assessment in clinical trials. The SMNP adjuvant is already under evaluation in HIV vaccine trials, which may provide essential safety and immunogenicity data supporting eventual human application of the combined adjuvant strategy. Such translational steps will be pivotal in confirming the approach’s effectiveness in humans and guiding its deployment.

Ultimately, this research embodies a significant leap forward in vaccine science by integrating foundational immunological principles with cutting-edge nanotechnology and biochemical engineering. The ability to engineer slow-release, follicle-targeted vaccines that magnify germinal center B cell diversity and expansion holds transformative potential for controlling infectious diseases that have so far eluded effective immunization.

Subject of Research: Animals
Article Title: Vaccines combining slow release and follicle targeting of antigens increase germinal center B cell diversity and clonal expansion
News Publication Date: 18-Jun-2025
Web References: http://dx.doi.org/10.1126/scitranslmed.adw7499
Image Credits: MIT

Keywords

Health and medicine, Vaccine research, Vaccine development, Life sciences, Human immunodeficiency virus, Chemical engineering

MIT researchers have harnessed the potential of biodegradable microparticles capable of timed release, effectively allowing multiple vaccine doses to be delivered from a single injection. This innovation promises to eliminate the common issue of missed follow-up doses by encapsulating vaccines in polymer particles engineered to release their payloads weeks or even months apart after injection. This methodology represents a powerful leap toward “self-boosting” vaccines, where a single shot can emulate the effect of multiple vaccinations over time, drastically simplifying immunization logistics.

Demonstrating their concept in a recent study published in Advanced Materials, the MIT team successfully designed microparticles that released two doses of a diphtheria toxoid vaccine. The particles discharged one dose immediately and a second dose two weeks later. Mouse models receiving this dual-release vaccine showed antibody responses indistinguishable from those given two separate injections spaced two weeks apart. This compelling proof of concept establishes a foundation for future vaccines that can maintain efficacy while minimizing patient visits and healthcare burdens.

A critical hurdle in single-shot vaccines lies in the stability and controlled release of vaccine antigens over extended periods. In this context, the MIT researchers explored polymers with unique properties suitable for programmable, pulsatile release. Prior work at MIT had employed PLGA (poly(lactic-co-glycolic acid)) as a carrier polymer. Although PLGA particles can deliver staggered doses, their biodegradation results in an acidic microenvironment that threatens the integrity of embedded vaccines, potentially reducing efficacy.

To overcome this obstacle, the latest investigation pivoted towards polyanhydride polymers, developed originally by MIT’s Robert Langer over four decades ago. Unlike PLGA, polyanhydrides are highly hydrophobic and, upon degradation, produce minimal acidic byproducts. This characteristic is crucial for preserving the potency of sensitive vaccine antigens during the extended release period. The hydrophobic nature slows erosion, enabling more precise control over the timing and kinetics of antigen liberation.

The researchers engineered a diverse library of 23 polyanhydride polymers by varying the chemical structures and ratios of two monomer components. Each polymer type was systematically scrutinized for its thermal stability at slightly elevated temperatures (around 104°F or 40°C) and suitability for microparticle fabrication using a proprietary “stamped assembly of polymer layers” (SEAL) process. This novel fabrication technique uses silicone molds to form cup-shaped particles that are filled with vaccine before sealing with a polymer cap. Only polymers that exhibited mechanical robustness and reliable sealing were selected for further testing, narrowing the candidates to six top-performing materials.

Tailoring these six polymers, the team developed microparticles programmed to release a delayed dose of diphtheria toxoid two weeks post-injection. These particles were co-administered with immediate-release vaccines in mouse models. Serological analyses four weeks after administration revealed antibody titers comparable to those induced by the conventional two-dose regimen, validating the functionality of this self-boosting vaccine delivery system.

Beyond physical experiments, the group integrated machine learning to accelerate polymer screening. By inputting variables such as monomer type, composition ratio, molecular weight, and vaccine loading capacity, a predictive model was trained to forecast degradation timelines and corresponding release profiles. This approach enabled rapid in silico evaluation of nearly 500 potential polymer candidates, guiding experimental efforts towards the most promising formulations. Subsequent validation in buffer solutions confirmed the model’s accuracy, demonstrating the power of computational tools in streamlining biomaterial development.

Looking forward, such machine learning-driven frameworks could be instrumental in engineering microparticles that release their payloads over significantly extended timeframes—spanning months or even years. Extending the release interval would be a game-changer for childhood vaccines traditionally requiring multiple doses over prolonged schedules, such as those for polio. This capability could facilitate single-administration vaccines that confer long-lasting immunity, dramatically improving global vaccination coverage.

Adjustments to polymer chemistry offer pathways to further modulate release kinetics. For example, increasing molecular weight or enhancing polymer hydrophobicity could slow erosion rates, while incorporating cross-linking agents might prolong particle retention and delay antigen release. These chemical modifications provide a versatile toolkit for designing delivery platforms tailored to specific vaccine schedules and pharmacodynamics.

These microparticles are not limited to diphtheria or childhood immunizations. The researchers envision extending this technology to a wide array of vaccines and therapeutics, particularly where antigen stability and acidity intolerance pose formulation challenges. The platform could be adapted for small molecules or biologics requiring multiple doses or durable presence in the body, addressing challenges beyond conventional vaccination.

According to lead author Linzixuan (Rhoda) Zhang and senior investigator Ana Jaklenec, the long-term goal is to make immunization more accessible, especially for populations with limited healthcare infrastructure, including rural areas of developed countries and resource-constrained regions globally. By reducing the necessity for repeated healthcare visits, these innovations hold potential to diminish disparities in vaccine coverage and ultimately save millions of lives.

The successful convergence of material science, innovative fabrication methods, immunology, and computational modeling represented in this work exemplifies the multidisciplinary efforts required to tackle complex global health issues. This leap forward in programmable vaccine delivery heralds a new era where vaccines are not only potent and safe but also smarter and significantly more convenient to administer on a global scale.

Subject of Research: Development of polyanhydride-based polymer microparticles for timed, pulsatile release of diphtheria toxoid vaccine to enable single-injection self-boosting immunization.

Article Title: Polyanhydride-Based Microparticles for Programmable Pulsatile Release of Diphtheria Toxoid (DT) for Single-Injection Self-Boosting Vaccines

News Publication Date: 15-May-2025

Web References:
DOI: 10.1002/adma.202501168

Image Credits: MIT

Keywords: Health and medicine, Preventive medicine, Vaccination, Vaccine introduction, Clinical medicine, Drug delivery, Drug delivery systems, Microparticles